Our laboratory has focused on the discovery and evaluation of functional protein-protein interactions in the context of human disease for the development of ligand-directed targeted therapies and imaging agents. Over the past five years, we have identified molecular targets in cancer and obesity. Recently, we introduced novel combinatorial approaches for mapping molecular diversity based on in vivo phage display, hybridoma-free generation of monoclonal antibodies and nanotechnology.